The first patient has been enrolled in a phase 1 clinical trial to evaluate the safety of a single intravitreal injection of THR-687 in the treatment of diabetic macular edema, according to a press release from Oxurion.
The open-label, multicenter, dose-escalation study will assess the safety of intravitreal injections of escalating dose levels of THR-687 in a maximum of 18 patients with DME.
THR-687 is a novel pan-RGD integrin antagonist that has been demonstrated in preclinical studies to target multiple aspects of retinal vascular disease, such as vessel leakage, inflammation and
Uncategorized